Clinical Trial Update: Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating biomarker changes after sargramostim treatment in Parkinson's disease; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease
• Parkinsonism

Drugs mentioned

• Leukine (sargramostim)

Snippet

Sponsor: University of Nebraska | Conditions: Parkinson's Disease and Parkinsonism | Phase 1 | Status: COMPLETED